← Back to Screener
Evolus, Inc. Common Stock (EOLS)
Price$4.53
Favorite Metrics
Price vs S&P 500 (26W)-29.43%
Price vs S&P 500 (4W)-9.96%
Market Capitalization$301.23M
All Metrics
Book Value / Share (Quarterly)$0.09
P/TBV (Annual)11.56x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)25.99%
Cash Flow / Share (Quarterly)$-0.78
Price vs S&P 500 (YTD)-33.02%
Gross Margin (TTM)66.33%
Net Profit Margin (TTM)-17.38%
EPS (TTM)$-0.80
10-Day Avg Trading Volume0.70M
EPS Excl Extra (TTM)$-0.80
Revenue Growth (5Y)39.38%
EPS (Annual)$-0.80
ROI (Annual)-39.69%
Gross Margin (Annual)66.33%
Net Profit Margin (5Y Avg)-32.77%
Cash / Share (Quarterly)$0.83
Revenue Growth QoQ (YoY)14.38%
ROA (Last FY)-22.86%
Revenue Growth TTM (YoY)11.61%
EBITD / Share (TTM)$-0.42
ROE (5Y Avg)-308.23%
Operating Margin (TTM)-10.99%
Cash Flow / Share (Annual)$-0.78
P/B Ratio54.55x
P/B Ratio (Quarterly)126.60x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.32x
Net Interest Coverage (TTM)-1.87x
ROA (TTM)-23.29%
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)1.90x
Quick Ratio (Quarterly)1.49x
3-Month Avg Trading Volume1.15M
52-Week Price Return-54.92%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.31
P/S Ratio (Annual)1.01x
Asset Turnover (Annual)1.32x
52-Week High$12.28
Operating Margin (5Y Avg)-27.55%
EPS Excl Extra (Annual)$-0.80
CapEx CAGR (5Y)21.90%
26-Week Price Return-25.44%
Quick Ratio (Annual)1.49x
13-Week Price Return-19.76%
Total Debt / Equity (Annual)22.00x
Current Ratio (Quarterly)1.90x
Enterprise Value$393.498
Revenue / Share Growth (5Y)22.42%
Asset Turnover (TTM)1.34x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)5.12x
Pretax Margin (Annual)-17.15%
Cash / Share (Annual)$0.83
3-Month Return Std Dev89.54%
Gross Margin (5Y Avg)64.30%
Net Income / Employee (TTM)$-0
ROE (Last FY)-913.07%
Net Interest Coverage (Annual)-1.87x
EPS Basic Excl Extra (Annual)$-0.80
P/FCF (TTM)28.26x
Receivables Turnover (TTM)5.81x
Total Debt / Equity (Quarterly)22.00x
EPS Incl Extra (TTM)$-0.80
Receivables Turnover (Annual)5.81x
ROI (TTM)-37.81%
P/S Ratio (TTM)1.01x
Pretax Margin (5Y Avg)-32.64%
Revenue / Share (Annual)$4.61
Tangible BV / Share (Annual)$0.56
Price vs S&P 500 (52W)-84.75%
Year-to-Date Return-30.38%
5-Day Price Return9.20%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-27.43%
Net Profit Margin (Annual)-17.38%
Month-to-Date Return12.65%
Cash Flow / Share (TTM)$-1.03
EBITD / Share (Annual)$-0.42
Operating Margin (Annual)-10.99%
LT Debt / Equity (Annual)22.00x
ROI (5Y Avg)-50.30%
LT Debt / Equity (Quarterly)22.00x
EPS Basic Excl Extra (TTM)$-0.80
P/TBV (Quarterly)36.12x
P/B Ratio (Annual)126.60x
Inventory Turnover (TTM)5.12x
Pretax Margin (TTM)-17.15%
Book Value / Share (Annual)$0.09
Price vs S&P 500 (13W)-20.45%
Beta1.19x
Revenue / Share (TTM)$4.58
ROE (TTM)-410.18%
52-Week Low$3.86
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EOLSEvolus, Inc. Common Stock | 1.01x | 11.61% | 66.33% | — | $4.53 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Evolus Inc commercializes Jeuveau, a purified botulinum toxin formulation used to treat moderate to severe frown lines. The company generates revenue from product sales in the United States and Europe, and from distribution partnerships in Canada. Evolus operates in the self-pay aesthetic market, targeting physicians and consumers seeking non-invasive cosmetic treatments.